Lexicon Pharmaceuticals, Inc. (LXRX) News
Follow Lexicon Pharmaceuticals, Inc. (LXRX) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 14 public stories across 10 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Lexicon Pharma Price Target Announced at $8.00/Share by Cantor Fitzgerald
Ratings actions from Benzinga
NEWS | Sep 28, 2026, 10:50 AM UTC
L
Cantor Fitzgerald initiates coverage of Lexicon Pharmaceuticals with Overweight rating, $8 price target
Cantor Fitzgerald initiated coverage on Lexicon Pharmaceuticals's stock with a rating of Overweight and a price target of $8.00.The price target implies an upside of 345.7% from the Sep 25 close of $1.79.Key takeaways fr
EQUITY | Sep 28, 2026, 10:39 AM UTC
H
Why Tempest Therapeutics Shares Are Trading Higher By Around 50%; Here Are 20 Stocks Moving Premarket
Shares of Tempest Therapeutics Inc (NASDAQ: TPST ) rose sharply in pre-market trading after the California-based clinical-stage biotechnology company announced an exclusive option agreement with Hebei Senlang Biotechnolo
LIVE | Sep 16, 2026, 09:04 AM UTC
L
LXRX to expect Phase III HCM data in Q1; resubmits type 1 diabetes NDA
LXRX is advancing sotagliflozin in HCM with Phase III data expected in Q1. The company is also preparing a type 1 diabetes NDA resubmission after meeting FDA safety requirements.
EQUITY | Sep 10, 2026, 08:16 PM UTC
L
Lexicon plans SONATA-HCM phase III Q1 2027 data; T1D resubmission set
The summit said SONATA-HCM phase III data are expected in Q1 2027. It also cited FDA requirement meeting for SOTA in T1D and a planned T1D resubmission for Q4, alongside pipeline and partnership efforts.
REGULATION | Sep 09, 2026, 05:54 PM UTC
M
LXRX Phase III sotagliflozin HCM data expected in Q1 2027
LXRX expects key Phase III sotagliflozin data in HCM in Q1 2027, with commercial preparations underway. For T1D, an FDA resubmission is planned for Q4 as regulatory progress continues.
REGULATION | Sep 09, 2026, 04:41 PM UTC
L
Lexicon Pharmaceuticals management to present at three upcoming investor conferences
Lexicon Pharmaceuticals said management will present at three upcoming investor conferences in New York, including the Citi 2026 Biopharma Back to School Conference on Sept. 9, 2026 (11:20 a.m.–11:55 a.m.).
EQUITY | Sep 01, 2026, 08:07 PM UTC
L
Lexicon Pharmaceuticals to participate in three investor conferences
Lexicon Pharmaceuticals plans to participate in three upcoming investor conferences.
EQUITY | Sep 01, 2026, 08:05 PM UTC
L
Lexicon earns third $10M milestone from Novo Nordisk
Lexicon Pharmaceuticals says it earned a third $10 million milestone payment from Novo Nordisk after a key phase 1 development milestone for LX9851.
MNA | Aug 24, 2026, 12:31 PM UTC
M
Lexicon earns third $10 million Novo Nordisk milestone payment
Lexicon Pharmaceuticals says it earned a third $10 million milestone payment from Novo Nordisk after achieving a key Phase 1 development milestone for LX9851.
MNA | Aug 24, 2026, 12:30 PM UTC
L
LXRX - Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
LXRX - Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
EARNINGS | Aug 06, 2026, 11:30 AM UTC
L
LXRX - Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
LXRX - Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
EARNINGS | Jul 30, 2026, 12:31 PM UTC
L
LXRX - Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and
LXRX - Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
EQUITY | Jul 27, 2026, 12:30 PM UTC
L
LXRX Remain bullish ahead of SONATA-HCM – expected to be a major stock-moving event @ Piper
LXRX Remain bullish ahead of SONATA-HCM – expected to be a major stock-moving event @ Piper
EQUITY | Jul 24, 2026, 01:12 PM UTC